2007 Fiscal Year Final Research Report Summary
New paradigm for therapy for pulmonary hypertension
| Project/Area Number |
18591726
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Anesthesiology/Resuscitation studies
|
|---|
| Research Institution | Jikei University School of Medicine |
|---|
Principal Investigator |
UEZONO Shoichi Jikei University School of Medicine, School of Medicine, Professor (10291676)
|
|---|
| Project Period (FY) |
2006 – 2007
|
| Keywords | pulmonary hypertension / pulmonary vascular remodeling / transcription factor / Egr-1 / KLF5 / antisense |
|---|
| Research Abstract |
Hypertensive pulmonary vascular disease is characterized by abnormal proliferation of vascular endothelial and smooth muscle cells, leading to pulmonary arterial hypertension (PAH), and death. Early growth response 1 (Egr-1) is a transcription factor that is rapidly activated after vascular injury, which plays an important role in vascular remodeling. We studied whether Egr-1 is a therapeutic target for PAH. o achieve effective suppression of Egr-1 in vivo, transfection with synthetic double-stranded Egr-1 decoy oligodeonucleotides was utilized in this study. Four-week-old Sprague-Dawley rats were evaluated for the development of PAH following monocrotaline (MCT, 60mg/kg) injection. Four hours prior to and just before MCT administration, either Egr-1 decoy or scrambled decoy was transfected using the hemagglutinating virus of Japan envelope vector system. Transfection of Egr-1 decoy but not scrambled decoy markedly attenuated MCT-induced PAH (mPAP=35±1 vs. 56±2, P<0.05) and vascular remodeling (VOS=0.39± 0.06 vs. 1.19±0.05, P<0.05). Egr-1 decoy may represent an effective strategy in the treatment of PAH, which provide the functional importance of Egr-1 in the MCT-induced PAH. We also investigated whether KLF 5, other transcription factor which is believed to play a pivotal role in vascular remodeling, has any impact on pulmonary vascular remodeling. Unfortunately, Am 80, a drug to suppress KLF 5 activity failed to reduce PA pressure in MCT induced PH in rats. We concluded KLF5 may not be a therapeutic target for PAH.
|
